Skip to content

Debt-to-equity at other companies

ALN
Alnylam PharmaceuticalsALNY
0.2×-0.4×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
0.1×0.0×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0.4×+0.3×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
0.2×+0.2×
Vor Biopharma logo
Vor BiopharmaVOR
0.5×+0.2×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
0.3×-0.8×

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$860.66M+305%
Enterprise value$850.62M+324%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Current ratio22.3×-6.1×

Where this comes from

Calculated from Design Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Design Therapeutics, Inc.'s debt-to-equity?
Design Therapeutics, Inc. (DSGN) reported debt-to-equity of 0× in Q1 2026.
How has Design Therapeutics, Inc.'s debt-to-equity changed year-over-year?
Design Therapeutics, Inc.'s debt-to-equity increased by 33.0% year-over-year, from 0× to 0×.
What is the long-term trend for Design Therapeutics, Inc.'s debt-to-equity?
Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s debt-to-equity has grown at a -6.7% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.